In Q2, Sanofi continued its solid growth momentum driven by a strong showing from Dupixent and the Consumer Healthcare Business. Although, Vaccines’ growth came in slightly lower than the other segments, this is not a reason to worry considering the underlying strength of the business, especially the flu vaccine. Moreover, the sustained profitability improvement meant that the firm’s transformation journey remained on track. Hence, our positive outlook on the stock is maintained.
28 Jul 2022
Strong Q2; full-year outlook revised upwards
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong Q2; full-year outlook revised upwards
In Q2, Sanofi continued its solid growth momentum driven by a strong showing from Dupixent and the Consumer Healthcare Business. Although, Vaccines’ growth came in slightly lower than the other segments, this is not a reason to worry considering the underlying strength of the business, especially the flu vaccine. Moreover, the sustained profitability improvement meant that the firm’s transformation journey remained on track. Hence, our positive outlook on the stock is maintained.